Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $139000.0.

  • Ernexa Therapeutics' Other Accumulated Expenses fell 6997.84% to $139000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $139000.0, marking a year-over-year decrease of 6997.84%. This contributed to the annual value of $226000.0 for FY2024, which is 5551.18% down from last year.
  • Latest data reveals that Ernexa Therapeutics reported Other Accumulated Expenses of $139000.0 as of Q3 2025, which was down 6997.84% from $438000.0 recorded in Q2 2025.
  • Ernexa Therapeutics' 5-year Other Accumulated Expenses high stood at $2.6 million for Q3 2022, and its period low was $45000.0 during Q1 2022.
  • In the last 5 years, Ernexa Therapeutics' Other Accumulated Expenses had a median value of $512000.0 in 2024 and averaged $671582.0.
  • Over the last 5 years, Ernexa Therapeutics' Other Accumulated Expenses had its largest YoY gain of 59555.56% in 2023, and its largest YoY loss of 7809.67% in 2023.
  • Ernexa Therapeutics' Other Accumulated Expenses (Quarter) stood at $617661.0 in 2021, then dropped by 4.48% to $590000.0 in 2022, then dropped by 13.9% to $508000.0 in 2023, then plummeted by 55.51% to $226000.0 in 2024, then crashed by 38.5% to $139000.0 in 2025.
  • Its Other Accumulated Expenses stands at $139000.0 for Q3 2025, versus $438000.0 for Q2 2025 and $460000.0 for Q1 2025.